This study is looking at a drug called elamipretide in healthy adults aged 65 to 80. The main goal is to see if daily injections of elamipretide are safe and well-tolerated over 4 weeks. Researchers will also look at changes in inflammation markers in the blood and how it might affect physical function. You might be able to join if you are 65-80 years old, can walk on your own, and have certain levels of mitochondrial function (VO2peak). The study plans to enroll 30 participants. The current status of the study is unclear, so it's not known if they are actively recruiting.

Study design

This is a Phase 2a, open-label (meaning you and the study staff will know what treatment you are receiving), single-arm study involving 30 older adult participants.

What's involved

You would have baseline measurements, receive daily subcutaneous (under the skin) injections of elamipretide for 4 weeks, have a phone interview at 2 weeks, and attend post-intervention visits.

Compensation

Not stated in the trial record.

Follow-up

After the last injection, participants will enter a 2-week follow-up period, ending with a final contact.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.